NOVO.B.DK

300.1

+1.18%↑

GMAB.DK

1,683

-1.72%↓

AMBUB.DK

62.45

+0.24%↑

NOVO.B.DK

300.1

+1.18%↑

GMAB.DK

1,683

-1.72%↓

AMBUB.DK

62.45

+0.24%↑

NOVO.B.DK

300.1

+1.18%↑

GMAB.DK

1,683

-1.72%↓

AMBUB.DK

62.45

+0.24%↑

NOVO.B.DK

300.1

+1.18%↑

GMAB.DK

1,683

-1.72%↓

AMBUB.DK

62.45

+0.24%↑

NOVO.B.DK

300.1

+1.18%↑

GMAB.DK

1,683

-1.72%↓

AMBUB.DK

62.45

+0.24%↑

Inicio・Lista de Acciones・Zealand Pharma A-S
Search

Zealand Pharma A-S

Cerrado

312.39 -6.61

Neutral

Precios actualizados 13 may 2026, 14:54 UTC

ComprarVender

Resumen

Variación precio

24h

Actual

Mínimo

310.39

Máximo

324.2

Métricas clave

By Trading Economics

Ingresos

-15M

-394M

Ventas

-35M

34M

P/B

Media del Sector

3.877

51.415

BPA

-5.58

Margen de beneficios

-1,158.824

Empleados

544

EBITDA

-26M

-529M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

+25.15% upside

Dividendos

By Dow Jones

Próximas Ganancias

13 ago 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

3.4B

24B

Apertura anterior

319

Cierre anterior

312.39

Zealand Pharma A-S Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

6 mar 2026, 09:24 UTC

Principales Movimientos del Mercado

Zealand Pharma Shares Plunge After Obesity Drug Candidate Disappoints in Trial

DJ

Leer

1 oct 2025, 08:54 UTC

Principales Movimientos del Mercado

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

DJ

Leer

6 mar 2026, 07:22 UTC

Charlas de Mercado

Roche, Zealand Pharma Obesity Drug Falls Short of Expectations -- Market Talk

DJ

Leer

Comparación entre iguales

Cambio de precio

Zealand Pharma A-S previsión

Precio Objetivo

By TipRanks

25.15% repunte

Estimación a 12 Meses

Media 270.582 DKK  25.15%

Máximo 270.568 DKK

Mínimo 270.568 DKK

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Zealand Pharma A-S Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

1 ratings

0

Comprar

1

Mantener

0

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Zealand Pharma A-S Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Zealand Pharma A-S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

Otras acciones del sector

NOVO.B.DK

Novo Nordisk A-S (Class B)

300.1

↑ +1.18%

GMAB.DK

Genmab A-S

1,683

↓-1.72%

AMBUB.DK

Ambu A-S

62.45

↑ +0.24%